Clinical trials of natural products as chemopreventive agents for prostate cancer

被引：48

作者：

Bemis, Debra L. ^{[1
]}

Katz, Aaron E. ^{[1
]}

Buttyan, Ralph ^{[1
]}

机构：

[1] Columbia Univ, Med Ctr, Dept Urol, Coll Phys & Surg, New York, NY 10032 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2006年 / 15卷 / 10期

关键词：

chemoprevention; clinical trials; green tea catechins; isoflavones; lycopene; pomegranate phenolics; prostate cancer; selenium; vitamin D; vitamin E; Zyflamend (R);

D O I：

10.1517/13543784.15.10.1191

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epidemiological research on prostate cancer risk in men throughout the world has identified significant correlations between dietary habits and prostate cancer occurrence. These studies served as a catalyst for exploration into the potential of dietary substances to act as chemopreventive agents against this disease, and include green tea catechins, lycopene, soy isoflavones, pomegranate phenolics, selenium, vitamins E and D, curcumin and resveratrol. Before these agents (in the dietary or purified forms) can be recommended as useful chemopreventive strategies for patients, their activity must be confirmed in rigorously designed clinical trials. This review discusses the preclinical and clinical data available for these dietary agents and describes relevant clinical trials currently being conducted.

引用

页码：1191 / 1200

页数：10

共 103 条

[1] Epidemiology of phytoestrogens [J].

Adlercreutz, M .

BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1998, 12 (04) :605-623

[2] Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) [J].

Ahonen, MH ;

Tenkanen, L ;

Teppo, L ;

Hakama, M ;

Tuohimaa, P .

CANCER CAUSES & CONTROL, 2000, 11 (09) :847-852

[3] Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance [J].

Akaza, H ;

Usami, M ;

Hinotsu, S ;

Ogawa, O ;

Kagawa, S ;

Kitamura, T ;

Tsukamoto, T ;

Naito, S ;

Hirao, Y ;

Murai, M ;

Yamanaka, H .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (06) :329-336

[4]

AKIYAMA T, 1987, J BIOL CHEM, V262, P5592

[5]

Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501

[6]

Ansari MS, 2004, BJU INT, V94, P678, DOI 10.1111/j.1464-410x.2003.05067_4.x

[7] A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer [J].

Ansari, MS ;

Gupta, NP .

BJU INTERNATIONAL, 2003, 92 (04) :375-378

[8] The role of α-tocopherol in preventing disease: from epidemiology to molecular events [J].

Azzi, A. ;

Gysin, R. ;

Kempna, P. ;

Ricciarelli, R. ;

Villacorta, L. ;

Visarius, T. ;

Zingg, J. -M. .

MOLECULAR ASPECTS OF MEDICINE, 2003, 24 (06) :325-336

[9] Development of weekly high-dose calcitriol based therapy for prostate cancer [J].

Beer, TM .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (05) :399-405

[10] Intermittent chemotherapy in metastatic androgen-independent prostate cancer [J].

Beer, TM ;

Garzotto, M ;

Henner, WD ;

Eilers, KM ;

Wersinger, EM .

BRITISH JOURNAL OF CANCER, 2003, 89 (06) :968-970

← 1 2 3 4 5 6 7 8 9 10 →